Sep. 4 at 6:04 PM
$AKTX
AKTX ADC platform use a proprietary linker, delivers its novel PH1 payload directly into the tumor.
Few months ago, Gilead’s acquisition of Tubulis with
$3.15 billion upfront plus up to
$1.85 billion in milestones. Mainly for Tubulis' s proprietary linker-payload technology, engineered to hold the payload in circulation and release it at the tumor.
